Lilly’s Cyramza Heading For Indian Debut?
This article was originally published in PharmAsia News
Executive Summary
Lilly appears to be on course to bringing its anticancer, Cyramza (ramucirumab), to India, after a key local expert panel recommended the product for marketing in two indications.